BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company’s bi-haptenized autologous ovarian cancer vaccine. The complete manufacturing of BVX-0918 from a cancer patient’s ovarian tumor now validates the production […]
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare Vancourver, BC – October 6, 2022 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that it has executed a binding Term Sheet (“Term Sheet” or “Agreement”) with Procare Health Iberia, S.L. (“Procare Health”), of […]
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Vancouver, BC – May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company’s autologous haptenized tumor cell vaccine for late-stage ovarian cancer. HCL has […]
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System (“Deaconess”). DRI, based […]
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE

VANCOUVER, BC – December 7, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV.CNQ) (OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect and prevent emerging infectious diseases, announced today that it has entered into a major sponsored research collaboration with The Ohio State University […]
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH

VANCOUVER, BC – November 9, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations. The objective of […]
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

Vancouver, BC – October 20, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA:5LB) (“BioVaxys” or “Company”) announced today that it has filed with the United States Patent & Trademark Office (“USPTO”) a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all […]
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION

Vancouver, BC – September 28, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission. Under the terms of a March 2021 agreement, global contract research organization (“CRO”) Inotiv, […]
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS

POTENTIAL FOR SUPERIOR TOLERABILITY TO MRNA AND ADENOVIRUS VECTOR VACCINES PRODUCTION AGREEMENT SIGNED WITH MILLIPORE-SIGMA FOR SARS-COV-2 VACCINE SUPPLY Vancouver, BC – September 23, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 […]
BIOVAXYS CANCER VACCINE MANUFACTURING PARTNER BIO ELPIDA REACHES BIOPRODUCTION MILESTONE

Vancouver, BC – September 17, 2021 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine and is beginning the next phase of manufacturing process development. Bio […]